These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35817239)

  • 1. Non-active site mutations in the HIV protease: Diminished drug binding affinity is achieved through modulating the hydrophobic sliding mechanism.
    Sherry D; Pandian R; Sayed Y
    Int J Biol Macromol; 2022 Sep; 217():27-41. PubMed ID: 35817239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
    Goldfarb NE; Ohanessian M; Biswas S; McGee TD; Mahon BP; Ostrov DA; Garcia J; Tang Y; McKenna R; Roitberg A; Dunn BM
    Biochemistry; 2015 Jan; 54(2):422-33. PubMed ID: 25513833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
    Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
    J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.
    Louis JM; Zhang Y; Sayer JM; Wang YF; Harrison RW; Weber IT
    Biochemistry; 2011 May; 50(21):4786-95. PubMed ID: 21446746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease.
    Foulkes-Murzycki JE; Scott WR; Schiffer CA
    Structure; 2007 Feb; 15(2):225-33. PubMed ID: 17292840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics.
    Sherry D; Worth R; Ismail ZS; Sayed Y
    J Mol Graph Model; 2021 Jul; 106():107931. PubMed ID: 34030114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.
    Velazquez-Campoy A; Muzammil S; Ohtaka H; Schön A; Vega S; Freire E
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):311-28. PubMed ID: 14754432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
    C S V; Tamizhselvi R; Munusami P
    J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.
    Cai Y; Schiffer C
    Methods Mol Biol; 2012; 819():551-60. PubMed ID: 22183557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
    Karnati KR; Wang Y
    J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.
    Ragland DA; Nalivaika EA; Nalam MN; Prachanronarong KL; Cao H; Bandaranayake RM; Cai Y; Kurt-Yilmaz N; Schiffer CA
    J Am Chem Soc; 2014 Aug; 136(34):11956-63. PubMed ID: 25091085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
    Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
    J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
    J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.
    Agniswamy J; Shen CH; Aniana A; Sayer JM; Louis JM; Weber IT
    Biochemistry; 2012 Apr; 51(13):2819-28. PubMed ID: 22404139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.